Simultaneous one-step regulation of planarization and donor rotation to enhance multi-modal imaging guided therapy

Zhang, Yize; Wang, Junjun; Wang, Shen; Zhu, Xiaojiao; Yu, Zhipeng; Wu, Zhichao; Yu, Jianhua; Zhou, Hongping

doi:10.1039/d2qm00568a

Cited by 8 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to potential issues with surgical treatment, such as recurrence, researchers are exploring the possibility of combining the contrast agent with a therapeutic agent. Thus far, a range of multi-modal image-guided therapy cases have been reported, with most possessing longer emission wavelengths and AIE properties, which are particularly advantageous for achieving balance in FLI, PAI, and PTI [ 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 ]. The work of Tang et al in 2022 is very representative [ 93 ].…”

Section: Aiegen-based Multi-modal Imagingmentioning

confidence: 99%

Dual/Multi-Modal Image-Guided Diagnosis and Therapy Based on Luminogens with Aggregation-Induced Emission

Zhu,

2024

Molecules

View full text Add to dashboard Cite

The combination of multiple imaging methods has made an indelible contribution to the diagnosis, surgical navigation, treatment, and prognostic evaluation of various diseases. Due to the unique advantages of luminogens with aggregation-induced emission (AIE), their progress has been significant in the field of organic fluorescent contrast agents. Herein, this manuscript summarizes the recent advancements in AIE molecules as contrast agents for optical image-based dual/multi-modal imaging. We particularly focus on the exceptional properties of each material and the corresponding application in the diagnosis and treatment of diseases.

show abstract

Section: Aiegen-based Multi-modal Imagingmentioning

confidence: 99%

Dual/Multi-Modal Image-Guided Diagnosis and Therapy Based on Luminogens with Aggregation-Induced Emission

Zhu,

2024

Molecules

View full text Add to dashboard Cite

show abstract

“…(d) Infrared thermography of TPA‐OS, TPA‐T‐OS, and TPA‐2T‐OS after 10 min of laser irradiation. Source : Reprinted with permission from Zhang et al [75].…”

Section: Anticancer Application Of Aie‐active Type I Pssmentioning

confidence: 99%

“…Under the dark environment, it could not observe the fluorescence for all the groups, suggesting that these PSs were biosafe. After light irradiation, TPA‐2T‐OS could cause green fluorescence on the cell membrane and red fluorescence in the nucleus within 5 min, but the other two PSs showed similar phenomena needing 10 min (TPA‐T‐OS) and 15 min (TPA‐OS), which reflected the better phototherapeutic effect of TPA‐2T‐OS in cells [75].…”

Section: Anticancer Application Of Aie‐active Type I Pssmentioning

confidence: 99%

“…PSs were biosafe. After light irradiation, TPA-2T-OS could cause green fluorescence on the cell membrane and red fluorescence in the nucleus within 5 min, but the other two PSs showed similar phenomena needing 10 min (TPA-T-OS) and 15 min (TPA-OS), which reflected the better phototherapeutic effect of TPA-2T-OS in cells[75].Although TPA-2T-OS showed a desirable synergistic phototherapeutic effect in suppressing tumor growth, the maximal fluorescence in the NIR-I region still faces the challenge of not having enough penetration depth. Extending the fluorescence signal of synergistic phototherapeutic agents to the NIR-II region was pursued passionately.…”

mentioning

confidence: 94%

See 1 more Smart Citation

Recent advances in aggregation‐induced emission–active type I photosensitizers with near‐infrared fluorescence: From materials design to therapeutic platform fabrication

Xie,

Li,

Zhao

et al. 2023

Luminescence

View full text Add to dashboard Cite

Near‐infrared (NIR) fluorescence imaging–guided photodynamic therapy (PDT) technology plays an important role in treating various diseases and still attracts increasing research interests for developing novel photosensitizers (PSs) with outstanding performances. Conventional PSs such as porphyrin and rhodamine derivatives have easy self‐aggregation properties in the physiological environment due to their inherent hydrophobic nature caused by their rigid molecular structure that induces strong intermolecular stacking π–π interaction, leading to serious fluorescence quenching and cytotoxic reactive oxygen species (ROS) reduction. Meanwhile, hypoxia is an inherent barrier in the microenvironment of solid tumors, seriously restricting the therapeutic outcome of conventional PDT. Aforementioned disadvantages should be overcome urgently to enhance the therapeutic effect of PSs. Novel NIR fluorescence–guided type I PSs with aggregation‐induced emission (AIE), which features the advantages of improving fluorescent intensity and ROS generation efficiency at aggregation as well as outstanding oxygen tolerance, bring hope for resolving aforementioned problems simultaneously. At present, plenty of research works fully demonstrates the advancement of AIE‐active PDT based on type I PSs. In this review, cutting‐edge advances focusing on AIE‐active NIR type I PSs that include the aspects of the photochemical mechanism of type I ROS generation, various molecular structures of reported type I PSs with NIR fluorescence and their design strategies, and typical anticancer applications are summarized. Finally, a brief conclusion is obtained, and the underlying challenges and prospects of AIE‐active type I PSs are proposed.

show abstract

The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type‐I Photosensitizers

Ma,

Wang,

Tang

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Type‐I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages for treating hypoxic tumor. However, most of the reported type‐I PSs have a contingency of molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy transfer (EET) process. Therefore, it is urgent to understand molecular design mechanisms for type‐I PSs. In this review, the two ways to achieve the type‐I PSs, i.e., inhibiting EET process (type‐II) or enhancing ET process (type‐I), are detailly explained. In response, the current design strategies of type‐I PSs are summarized from two perspectives: indirect strategy (inhibiting EET process: reducing the energy of the lowest triplet excited state (T1) to lower than the energy required for the excitation energy transfer to produce singlet oxygen) and direct strategy (enhancing ET process: promoting the ET efficiency of PSs to generate superoxide radicals). The construction of direct strategy can be realized by forming an electron‐rich microenvironment, providing an electron‐deficient intermediate transmitter, and introducing an enhanced electron transfer capacity primitive.

show abstract

Simultaneous one-step regulation of planarization and donor rotation to enhance multi-modal imaging guided therapy

Abstract: The strategy of planarization and donor rotation has been widely applied to the design of theranostic agents due to the elevated intramolecular charge transfer (ICT) and non-radiative transitions. Herein, a...

Cited by 8 publications

References 44 publications

Dual/Multi-Modal Image-Guided Diagnosis and Therapy Based on Luminogens with Aggregation-Induced Emission

Dual/Multi-Modal Image-Guided Diagnosis and Therapy Based on Luminogens with Aggregation-Induced Emission

Recent advances in aggregation‐induced emission–active type I photosensitizers with near‐infrared fluorescence: From materials design to therapeutic platform fabrication

The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type‐I Photosensitizers

Contact Info

Product

Resources

About